Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7

Abstract

RMP-7, a bradykinin analog, has been shown to selectively open the blood-tumor barrier for the delivery of chemotherapeutic drugs to brain tumors. In contrast to bradykinin, RMP-7 has no hypotensive effects and has been approved for human use. This study was initiated to determine whether RMP-7 would open the blood-tumor barrier to virus vectors encoding tumor-killing genes in an experimental model. The herpes virus vector used, hrR3, which encodes virus thymidine kinase gene and the lacZ reporter gene, is defective in a gene encoding ribonucleotide reductase, replicates selectively in dividing tumor cells and not in postmitotic neural cells. It was determined that an optimum dose of RMP-7 (1.5–3.0 μg/kg over 10–15 minutes) enhanced viral delivery to brain tumors in rats bearing intracranial 9 L gliosarcomas when infused through the carotid artery immediately prior to virus vector application. Maximum expression of the lacZ reporter gene occurred at 3 days after intracarotid infusion. By 8 days, transgene expression was largely confined to tumor foci away from the main tumor mass. Viral delivery was essentially specific to tumor cells, with little transgene expression elsewhere in the brain. Minimal uptake and pathology was noted in the kidney, spleen, and liver. These findings indicate that intracarotid delivery of RMP-7 can augment the selective delivery of virus vectors to brain tumors in an experimental rat model, with the potential for application to human brain tumors.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Xandra O Breakefield.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Barnett, F., Rainov, N., Ikeda, K. et al. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther 6, 14–20 (1999). https://doi.org/10.1038/sj.cgt.7700003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700003

Keywords

  • Blood-brain barrier
  • blood-tumor barrier
  • carotid artery
  • gene therapy
  • herpes simplex virus type I
  • intra-arterial application.

Further reading

Search

Quick links